Acute Radiation Syndrome – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Acute Radiation Syndrome – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute Radiation Syndrome: Overview
Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person’s whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The amount of radiation that a person’s body absorbs is called the radiation dose. The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Types of radiation that can cause ARS include alpha radiation particles, beta radiation particles - charged particles (electrons), gamma rays, x-rays, neutrons etc.
Symptoms
The effects of exposure to radiations are nonspecific signs and symptoms such as nausea, emesis, fatigue, fever, Diarrhea, Headache, Dizziness and disorientation, Hair loss, Bloody vomit and stools from internal bleeding, low blood pressure and anorexia. The severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. The severity of radiation sickness also depends on sensitivity of the affected tissue like the gastrointestinal system and bone marrow are highly sensitive to radiation.
Diagnosis
A diagnosis of Acute Radiation Syndrome without any history of exposure to radiation is complicated as the symptoms are nonspecific. The quickest and easiest laboratory test to provide an estimate of exposure is by measuring an absolute lymphocyte count is. Cytogenetic dosimetry, the gold standard, relies on predictable and standardized effects of radiation on deoxyribonucleic acid (DNA) replication in cultured lymphocytes.
Treatment
Treatment of Acute Radiation Syndrome (ARS) focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. Some patients may benefit from treatments that help the bone marrow recover its function. Supportive care saves lives when it comes to acute radiation syndrome. The lower the radiation dose, the more likely it is that the person will recover from ARS. For survivors of ARS, the recovery process may last from several weeks up to 2 years. Prevention of thyroid cancer must be a priority. All children and pregnant women must be offered potassium iodide to protect the thyroid from the uptake of radioactive iodine.
Acute Radiation Syndrome Emerging Drugs Chapters
This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Radiation Syndrome Emerging Drugs
Further product details are provided in the report……..
Acute Radiation Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Acute Radiation Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acute Radiation Syndrome – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute Radiation Syndrome: Overview
Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person’s whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The amount of radiation that a person’s body absorbs is called the radiation dose. The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Types of radiation that can cause ARS include alpha radiation particles, beta radiation particles - charged particles (electrons), gamma rays, x-rays, neutrons etc.
Symptoms
The effects of exposure to radiations are nonspecific signs and symptoms such as nausea, emesis, fatigue, fever, Diarrhea, Headache, Dizziness and disorientation, Hair loss, Bloody vomit and stools from internal bleeding, low blood pressure and anorexia. The severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. The severity of radiation sickness also depends on sensitivity of the affected tissue like the gastrointestinal system and bone marrow are highly sensitive to radiation.
Diagnosis
A diagnosis of Acute Radiation Syndrome without any history of exposure to radiation is complicated as the symptoms are nonspecific. The quickest and easiest laboratory test to provide an estimate of exposure is by measuring an absolute lymphocyte count is. Cytogenetic dosimetry, the gold standard, relies on predictable and standardized effects of radiation on deoxyribonucleic acid (DNA) replication in cultured lymphocytes.
Treatment
Treatment of Acute Radiation Syndrome (ARS) focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. Some patients may benefit from treatments that help the bone marrow recover its function. Supportive care saves lives when it comes to acute radiation syndrome. The lower the radiation dose, the more likely it is that the person will recover from ARS. For survivors of ARS, the recovery process may last from several weeks up to 2 years. Prevention of thyroid cancer must be a priority. All children and pregnant women must be offered potassium iodide to protect the thyroid from the uptake of radioactive iodine.
Acute Radiation Syndrome Emerging Drugs Chapters
This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Radiation Syndrome Emerging Drugs
- HemaMax: Neumedicines
- Recilisib: Onconova Therapeutics
Further product details are provided in the report……..
Acute Radiation Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Radiation Syndrome
- Phases
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acute Radiation Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.
- In May 2020, Cellphire, announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).
- Acute Radiation Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Radiation Syndrome drugs?
- How many Acute Radiation Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Radiation Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Onconova Therapeutics
- Neumedicines
- Meabco
- Pluristem Therapeutics
- Valenta Pharmaceuticals
- Humanetics Corporation
- Abion
- Cleveland BioLabs
- Cellphire
- Chrysalis BioTherapeutics
- iNtRON Biotechnology
- Recilisib
- HemaMax
- BP-C2
- PLX R18
- Myelo 001
- BIO-300
- ABN-601
- Entolimod
- Thrombosomes
- TP508
- KMRC011
Introduction
Executive Summary
Acute Radiation Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute Radiation Syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Radiation Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Radiation Syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
HemaMax: Neumedicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIO 300: Humanetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BP-C2: Meabco
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute Radiation Syndrome Key Companies
Acute Radiation Syndrome Key Products
Acute Radiation Syndrome- Unmet Needs
Acute Radiation Syndrome- Market Drivers and Barriers
Acute Radiation Syndrome- Future Perspectives and Conclusion
Acute Radiation Syndrome Analyst Views
Acute Radiation Syndrome Key Companies
Appendix
Executive Summary
Acute Radiation Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute Radiation Syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Radiation Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Radiation Syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
HemaMax: Neumedicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BIO 300: Humanetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BP-C2: Meabco
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acute Radiation Syndrome Key Companies
Acute Radiation Syndrome Key Products
Acute Radiation Syndrome- Unmet Needs
Acute Radiation Syndrome- Market Drivers and Barriers
Acute Radiation Syndrome- Future Perspectives and Conclusion
Acute Radiation Syndrome Analyst Views
Acute Radiation Syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acute Radiation Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acute Radiation Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acute Radiation Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acute Radiation Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
